Search details
1.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36115523
2.
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Immunotherapy
; 15(11): 787-797, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37150956
Results
1 -
2
de 2
1
Next >
>>